Boehringer Ingelheim (BI) is celebrating after an independent evaluation in the UK has reconfirmed that the benefits of its clot-busting drug alteplase outweigh the risks for acute ischaemic stroke.

The drug has been approved for the treatment of acute myocardial infarction (AMI) by the FDA since 2000, and – while Roche doesn't separate Activase and TNKase sales in its financial reporting ...